Cargando…
Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma
PURPOSE: To determine whether [(18)F]FDG PET/CT-derived radiomic features alone or in combination with clinical, laboratory and biological parameters are predictive of 2-year progression-free survival (PFS) in patients with mantle cell lymphoma (MCL), and whether they enable outcome prognostication....
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879438/ https://www.ncbi.nlm.nih.gov/pubmed/31286200 http://dx.doi.org/10.1007/s00259-019-04420-6 |
_version_ | 1783473592351064064 |
---|---|
author | Mayerhoefer, Marius E. Riedl, Christopher C. Kumar, Anita Gibbs, Peter Weber, Michael Tal, Ilan Schilksy, Juliana Schöder, Heiko |
author_facet | Mayerhoefer, Marius E. Riedl, Christopher C. Kumar, Anita Gibbs, Peter Weber, Michael Tal, Ilan Schilksy, Juliana Schöder, Heiko |
author_sort | Mayerhoefer, Marius E. |
collection | PubMed |
description | PURPOSE: To determine whether [(18)F]FDG PET/CT-derived radiomic features alone or in combination with clinical, laboratory and biological parameters are predictive of 2-year progression-free survival (PFS) in patients with mantle cell lymphoma (MCL), and whether they enable outcome prognostication. METHODS: Included in this retrospective study were 107 treatment-naive MCL patients scheduled to receive CD20 antibody-based immuno(chemo)therapy. Standardized uptake values (SUV), total lesion glycolysis, and 16 co-occurrence matrix radiomic features were extracted from metabolic tumour volumes on pretherapy [(18)F]FDG PET/CT scans. A multilayer perceptron neural network in combination with logistic regression analyses for feature selection was used for prediction of 2-year PFS. International prognostic indices for MCL (MIPI and MIPI-b) were calculated and combined with the radiomic data. Kaplan–Meier estimates with log-rank tests were used for PFS prognostication. RESULTS: SUVmean (OR 1.272, P = 0.013) and Entropy (heterogeneity of glucose metabolism; OR 1.131, P = 0.027) were significantly predictive of 2-year PFS: median areas under the curve were 0.72 based on the two radiomic features alone, and 0.82 with the addition of clinical/laboratory/biological data. Higher SUVmean in combination with higher Entropy (SUVmean >3.55 and entropy >3.5), reflecting high “metabolic risk”, was associated with a poorer prognosis (median PFS 20.3 vs. 39.4 months, HR 2.285, P = 0.005). The best PFS prognostication was achieved using the MIPI-bm (MIPI-b and metabolic risk combined): median PFS 43.2, 38.2 and 20.3 months in the low-risk, intermediate-risk and high-risk groups respectively (P = 0.005). CONCLUSION: In MCL, the [(18)F]FDG PET/CT-derived radiomic features SUVmean and Entropy may improve prediction of 2-year PFS and PFS prognostication. The best results may be achieved using a combination of metabolic, clinical, laboratory and biological parameters. |
format | Online Article Text |
id | pubmed-6879438 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-68794382019-12-10 Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma Mayerhoefer, Marius E. Riedl, Christopher C. Kumar, Anita Gibbs, Peter Weber, Michael Tal, Ilan Schilksy, Juliana Schöder, Heiko Eur J Nucl Med Mol Imaging Original Article PURPOSE: To determine whether [(18)F]FDG PET/CT-derived radiomic features alone or in combination with clinical, laboratory and biological parameters are predictive of 2-year progression-free survival (PFS) in patients with mantle cell lymphoma (MCL), and whether they enable outcome prognostication. METHODS: Included in this retrospective study were 107 treatment-naive MCL patients scheduled to receive CD20 antibody-based immuno(chemo)therapy. Standardized uptake values (SUV), total lesion glycolysis, and 16 co-occurrence matrix radiomic features were extracted from metabolic tumour volumes on pretherapy [(18)F]FDG PET/CT scans. A multilayer perceptron neural network in combination with logistic regression analyses for feature selection was used for prediction of 2-year PFS. International prognostic indices for MCL (MIPI and MIPI-b) were calculated and combined with the radiomic data. Kaplan–Meier estimates with log-rank tests were used for PFS prognostication. RESULTS: SUVmean (OR 1.272, P = 0.013) and Entropy (heterogeneity of glucose metabolism; OR 1.131, P = 0.027) were significantly predictive of 2-year PFS: median areas under the curve were 0.72 based on the two radiomic features alone, and 0.82 with the addition of clinical/laboratory/biological data. Higher SUVmean in combination with higher Entropy (SUVmean >3.55 and entropy >3.5), reflecting high “metabolic risk”, was associated with a poorer prognosis (median PFS 20.3 vs. 39.4 months, HR 2.285, P = 0.005). The best PFS prognostication was achieved using the MIPI-bm (MIPI-b and metabolic risk combined): median PFS 43.2, 38.2 and 20.3 months in the low-risk, intermediate-risk and high-risk groups respectively (P = 0.005). CONCLUSION: In MCL, the [(18)F]FDG PET/CT-derived radiomic features SUVmean and Entropy may improve prediction of 2-year PFS and PFS prognostication. The best results may be achieved using a combination of metabolic, clinical, laboratory and biological parameters. Springer Berlin Heidelberg 2019-07-08 2019 /pmc/articles/PMC6879438/ /pubmed/31286200 http://dx.doi.org/10.1007/s00259-019-04420-6 Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Mayerhoefer, Marius E. Riedl, Christopher C. Kumar, Anita Gibbs, Peter Weber, Michael Tal, Ilan Schilksy, Juliana Schöder, Heiko Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma |
title | Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma |
title_full | Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma |
title_fullStr | Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma |
title_full_unstemmed | Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma |
title_short | Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma |
title_sort | radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879438/ https://www.ncbi.nlm.nih.gov/pubmed/31286200 http://dx.doi.org/10.1007/s00259-019-04420-6 |
work_keys_str_mv | AT mayerhoefermariuse radiomicfeaturesofglucosemetabolismenablepredictionofoutcomeinmantlecelllymphoma AT riedlchristopherc radiomicfeaturesofglucosemetabolismenablepredictionofoutcomeinmantlecelllymphoma AT kumaranita radiomicfeaturesofglucosemetabolismenablepredictionofoutcomeinmantlecelllymphoma AT gibbspeter radiomicfeaturesofglucosemetabolismenablepredictionofoutcomeinmantlecelllymphoma AT webermichael radiomicfeaturesofglucosemetabolismenablepredictionofoutcomeinmantlecelllymphoma AT talilan radiomicfeaturesofglucosemetabolismenablepredictionofoutcomeinmantlecelllymphoma AT schilksyjuliana radiomicfeaturesofglucosemetabolismenablepredictionofoutcomeinmantlecelllymphoma AT schoderheiko radiomicfeaturesofglucosemetabolismenablepredictionofoutcomeinmantlecelllymphoma |